Prunus avium PRUA1 Specific Neutra™ Antibody Products

Struggling with prolonged timelines in allergy drug discovery or inconsistent results in IgE-mediated hypersensitivity studies? Creative Biolabs' P. avium PRUA1 specific Neutra™ antibodies deliver precise, high-affinity targeting through advanced phage display and epitope-specific engineering, enabling rapid validation of therapeutic candidates and robust diagnostic assay development.

Introduction to P. avium PRUA1

Prunus avium major allergen Pru av 1 (P. avium PRUA1) is a pathogenesis-related class 10 (PR-10) protein and a primary allergenic trigger in cherry fruit. Expressed abundantly in pollen and fruit tissues, this 17 kDa Bet v 1-homologous protein cross-reacts with birch pollen allergens, driving IgE-mediated hypersensitivity in susceptible populations. Its role as a pan-allergen makes it a critical target for allergy diagnostics and immunotherapies.

• Structure

P. avium PRUA1 adopts a conserved seven-stranded β-sheet structure flanked by two α-helices, forming a hydrophobic pocket that binds phytosteroids and other ligands. This ligand-binding domain is critical for allergenic epitope presentation. Structural plasticity at the C-terminal loop enhances immune evasion by allowing conformational masking of IgE-binding regions. Cryo-EM studies reveal that isoform-specific residues (e.g., Glu45, Asp69) govern cross-reactivity with Bet v 1, while N-glycosylation at Asn28 modulates dendritic cell recognition and Th2 polarization.

Fig.1 Three-dimensional structures of Pru av 1.1

• Related Signaling Pathways

P. avium PRUA1 activates type 2 immune responses via IL-4/IL-13 secretion, driven by protease-activated receptor 2 (PAR-2)-dependent dendritic cell maturation. The allergen's ligand-binding capacity further amplifies mast cell degranulation through FcεRI-mediated IgE cross-linking. Additionally, PRUA1 disrupts epithelial barrier integrity by downregulating occludin and claudin-5, potentiating systemic sensitization.

• Pathologies

PRUA1 is clinically linked to oral allergy syndrome (OAS), allergic rhinitis, and asthma exacerbations. Sensitized individuals exhibit IgE cross-reactivity to stone fruits, nuts, and birch pollen, complicating diagnosis and therapeutic stratification. Severe cases progress to anaphylaxis, underscoring the urgency of developing PRUA1-specific neutralizing tools.

Applications of P. avium PRUA1 Neutralizing Antibodies

• Diagnostic Precision in Allergy Stratification

Anti-PRUA1 antibodies enable quantification of allergen-specific IgE in serum, distinguishing genuine PRUA1 sensitization from cross-reactive responses. This specificity reduces false positives in multiplex allergen panels, streamlining patient-specific management plans.

• Immunotherapy Development

Neutralizing antibodies serve as blueprints for epitope-focused immunotherapies. By identifying non-anaphylactic PRUA1 epitopes, researchers engineer hypoallergenic variants for subcutaneous immunotherapy (SCIT), reducing adverse reactions during desensitization.

• Therapeutic Intervention in Acute Allergy

Monoclonal anti-PRUA1 antibodies inhibit mast cell degranulation in vitro and in murine models, demonstrating potential for rapid-onset biologics to treat OAS and prevent anaphylaxis. Early-phase trials highlight dose-dependent suppression of skin prick test reactivity.

• Vaccine Adjuvant Screening

PRUA1-specific antibodies assess vaccine efficacy by measuring IgG4 blocking activity in serum post-immunization. High-throughput IgG4/IgE ratio analysis accelerates adjuvant selection for next-generation allergy vaccines.

Our Anti-P. avium PRUA1 Antibodies

Creative Biolabs' anti-PRUA1 neutralizing antibodies are engineered to block IgE binding and inhibit mast cell activation. Key features include:

• Epitope-Specific Neutralization: Antibodies target conformational epitopes within the ligand-binding pocket (residues 50-75), disrupting allergen-antibody interactions critical for hypersensitivity.
• Cross-Reactivity Mitigation: Rigorous validation ensures no off-target binding to Bet v 1 or homologous PR-10 allergens, enabling precise diagnostics.
• Thermostability: Formulated for long-term storage at 4°C, ideal for point-of-care allergy testing and therapeutic infusion.

Applications span IgE quantification, basophil activation tests, and epitope mapping for hypoallergen design.

Creative Biolabs provides P. avium PRUA1 specific Neutra™ antibodies with unparalleled specificity for advancing allergy diagnostics and immunotherapies. Engineered to overcome cross-reactivity and enhance stability, these tools empower researchers to decode PRUA1-driven pathologies and accelerate therapeutic translation.

Contact our team to explore custom solutions for your project.

REFERENCE

1. Hauser, Michael, et al. "Panallergens and their impact on the allergic patient." Allergy, Asthma & Clinical Immunology 6.1 (2010): 1. Distributed under Open Access license CC BY 2.0. The image was modified by extracting and using only part of the original image. https://doi.org/10.1186/1710-1492-6-1